Recurrent Aphthous Stomatitis (Investigational Adjunct)
Investigational adjunct for severe recurrent aphthous stomatitis; topical corticosteroids, chlorhexidine, and (for severe disease) colchicine or systemic immunomodulators remain evidence-based.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for recurrent aphthous stomatitis (canker sores). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for recurrent aphthous stomatitis is investigational and considered inappropriate.
- Какие доказательства существуют?
- Tier C (investigational). No published trials; only theoretical mention. Evidence-based therapy for recurrent aphthous stomatitis (canker sores): topical corticosteroid (triamcinolone in Orabase, fluocinonide), topical anesthetics (lidocaine 2%), antimicrobial mouthrinses (chlorhexidine), and systemic therapy (colchicine, dapsone, thalidomide) for severe major aphthous ulcers. Workup for underlying systemic disease (Behcet syndrome, IBD, celiac disease, HIV, hematinic deficiencies) in major or recurrent cases. Most minor canker sores heal in 7-14 days without intervention.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of oral inflammation or ulceration
- Bacterial superinfection of oral ulcers
- Local skin infection or, rarely, Aeromonas infection if leech placed near mouth
- Allergic reaction to leech saliva (uncommon)
- Intraoral leech placement is dangerous and not recommended
- Trigger of Behcet disease flares if underlying condition present
- Delay of workup for underlying systemic disease
- Кому не следует это рассматривать
- Patients with suspected Behcet syndrome, IBD, celiac disease, or HIV
- Patients with hematinic deficiencies (iron, folate, B12) not yet replaced
- Patients with active oral candidiasis or herpes simplex
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not tried topical corticosteroid or antimicrobial mouthrinse
- Pregnant patients
- О чём спросить врача
- Have I been worked up for Behcet syndrome (genital and ocular involvement)?
- Have I been tested for iron, folate, B12, and celiac disease?
- Have I tried topical triamcinolone in Orabase or fluocinonide?
- Am I a candidate for colchicine or systemic therapy for severe major aphthous?
- Could oral candidiasis or herpes simplex be mimicking aphthous ulcers?
- What evidence specifically supports leech therapy for canker sores?
- What is the cost and is it covered by insurance? (typically not covered)
- Когда срочно обратиться за медицинской помощью
- New genital ulcers, eye redness, or skin lesions (possible Behcet syndrome)
- Abdominal pain, diarrhea, or rectal bleeding (possible inflammatory bowel disease)
- Severe ulcers with high fever and difficulty swallowing
- Ulcers persisting more than 3 weeks (rule out malignancy)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Что это НЕ означает
- This is NOT FDA-cleared for recurrent aphthous stomatitis or canker sores.
- Theoretical mention does NOT establish efficacy versus topical corticosteroid, antimicrobial mouthrinse, or colchicine.
- It does NOT replace workup for Behcet syndrome, IBD, celiac disease, or hematinic deficiencies.
- It does NOT substitute for evidence-based topical therapy.
- It does NOT mean intraoral leech application is safe or appropriate.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- other
- ICD-10
- K12.0, K12.04
- Safety tier
- high
Evidence Summary
Recurrent aphthous stomatitis (RAS) is recurrent painful oral ulcers, classified as minor, major, or herpetiform. Evidence-based topical therapy includes triamcinolone or clobetasol in adhesive bases, chlorhexidine rinses, topical anesthetics, and topical sucralfate. Severe or major RAS may warrant colchicine, dapsone, thalidomide (with strict regulatory controls), or systemic corticosteroids. Workup excludes Behcet disease, celiac disease, nutritional deficiencies (B12, folate, iron, zinc), HIV, and inflammatory bowel disease in atypical or severe cases. No published controlled trials of hirudotherapy exist for RAS. Oral mucosal placement of leeches is anatomically inappropriate and uniquely dangerous (airway, swallowing, hemorrhage); any rationale must be extra-oral application without plausible mucosal-targeted mechanism.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Intra-oral placement (absolute — airway and hemorrhage risk)
- Lip placement
- Active major RAS or herpetiform RAS with confluent ulcers
- Behcet disease without rheumatology workup
- Underlying nutritional deficiency not corrected
- Immunocompromise (HIV, IBD on immunosuppression)
Related Conditions
Metabolic Syndrome (Investigational Adjunct)
Investigational adjunct to lifestyle modification in metabolic syndrome; small case series only; weight loss, dietary modification, and pharmacotherapy remain primary.
Hashimoto's Thyroiditis (Investigational Cervical Adjunct)
Highly investigational adjunct in stable Hashimoto's thyroiditis; case reports only; levothyroxine replacement remains primary.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (Investigational Adjunct)
Investigational adjunct for ME/CFS symptom management; pacing strategies, post-exertional malaise avoidance, and individualized supportive care remain primary; graded exercise therapy is no longer recommended per updated NICE guidance.
Stage III Postsurgical Lymphedema (Highly Investigational Adjunct)
Highly investigational adjunct for advanced postsurgical lymphedema; complete decongestive therapy and (selectively) surgical options (LVA, VLNT) remain evidence-based.